Skip to main content

Articles

Page 5 of 5

  1. We recently developed a chelating platform based on the macrocycle 1,4,7-triazacyclononane with up to three, five-membered azaheterocyclic arms for the development of 68Ga- and 64Cu-based radiopharmaceuticals. He...

    Authors: Tilman Läppchen, Jason P. Holland, Yvonne Kiefer and Mark D. Bartholomä
    Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:6
  2. 99mTc-mercaptoacetyl-triglycine (99mTc-MAG3) has been used for dynamic renal imaging since about 30 years. Free pertechnetate (99mTcO4), colloidal 99mTc ((99mTcO2)n), 99mTc-tartrate (precursor), precomplexes (99m

    Authors: Marietta Straub, Michel Leresche, Claude Pilloud, Fabien Devynck, Nicolas Stritt and Rolf Hesselmann
    Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:5
  3. Overexpression of prostatic membrane antigen (PSMA) is associated with the progression and prognosis of prostate cancer. There are numerous studies using this peptide with the 68Ga radionuclide. Previous methods ...

    Authors: Javier Giglio, Maia Zeni, Eduardo Savio and Henry Engler
    Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:4
  4. The global network of cyclotrons has expanded rapidly over the last decade. The bulk of its industrial potential is composed of small medical cyclotrons with a proton energy below 20 MeV for radionuclides prod...

    Authors: Mateusz Adam Synowiecki, Lars Rutger Perk and J. Frank W. Nijsen
    Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:3
  5. Current analytical methods for characterizing pharmacokinetic and metabolic properties of positron emission tomography (PET) and single photon emission computed tomography (SPECT) probes are limited. Alternati...

    Authors: Eszter Boros, Omar R. Pinkhasov and Peter Caravan
    Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:2
  6. Analogues of exendin-4 have been radiolabeled for imaging the glucagon-like peptide type 1 receptors (GLP-1R) which are overexpressed in insulinoma. The aim of this research was to synthesize an 18F–labeled silic...

    Authors: Lukas O. Dialer, Andreas Jodal, Roger Schibli, Simon M. Ametamey and Martin Béhé
    Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:1
  7. Given the increasing exploration of fluorescent tracers in the field of nuclear medicine, a need has risen for practical development guidelines that can help improve the translation aspects of fluorescent trac...

    Authors: Fijs W. B. van Leeuwen, Bart Cornelissen, Federico Caobelli, Laura Evangelista, Latifa Rbah-Vidal, Silvana Del Vecchio, Catarina Xavier, Jacques Barbet and Marion de Jong
    Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:15
  8. The favorable decay properties of 43Sc and 44Sc for PET make them promising candidates for future applications in nuclear medicine. An advantage 43Sc (T1/2 = 3.89 h, Eβ+ av = 476 keV [8...

    Authors: Katharina A. Domnanich, Robert Eichler, Cristina Müller, Sara Jordi, Vera Yakusheva, Saverio Braccini, Martin Behe, Roger Schibli, Andreas Türler and Nicholas P. van der Meulen
    Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:14
  9. Carbon-11 labeled L-methionine (11C–MET) is a popular tracer used in the clinic for imaging brain tumors with positron emission tomography. However, the stability of 11C–MET in its final formulation is not well d...

    Authors: Michael Woods, Leo Leung, Kari Frantzen, Jennifer G. Garrick, Zhengxing Zhang, Chengcheng Zhang, Wade English, Don Wilson, François Bénard and Kuo-Shyan Lin
    Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:13
  10. The EU regulation 536/2014 aims to facilitate the experimental use of diagnostic radiopharmaceuticals in particular for GMP requirements and needs to be applied in EU countries. As definitely clarified by this...

    Authors: G. Bormans, A. Buck, A. Chiti, M. Cooper, J. Croasdale, M. Desruet, V. Kumar, Y. Liu, I. Penuelas, C. Rossetti, R. Schiavo, S. W. Schwarz and A. D. Windhorst
    Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:12
  11. The synthesis of [11C]L-deprenyl-D2 for imaging of astrocytosis with positron emission tomography (PET) in neurodegenerative diseases has been previously reported. [11C]L-deprenyl-D2 radiosynthesis requires a pre...

    Authors: Kevin Zirbesegger, Pablo Buccino, Ingrid Kreimerman, Henry Engler, Williams Porcal and Eduardo Savio
    Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:10
  12. The importance of the sulfur-fluorine bond is starting to increase in modern medicinal chemistry literature. This is due to a better understanding of the stability and reactivity of this moiety depending on th...

    Authors: Giancarlo Pascali, Lidia Matesic, Bo Zhang, Andrew T. King, Andrea J. Robinson, Alison T. Ung and Benjamin H. Fraser
    Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:9
  13. Validation and qualification activities are nowadays an integral part of the day by day routine work in a radiopharmacy. This document is meant as an Appendix of Part B of the EANM “Guidelines on Good Radiopha...

    Authors: S. Todde, P. Kolenc Peitl, P. Elsinga, J. Koziorowski, V. Ferrari, E. M. Ocak, O. Hjelstuen, M. Patt, T. L. Mindt and M. Behe
    Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:8
  14. [18F]AV1451 is a commonly used radiotracer for imaging tau deposits in Alzheimer’s disease (AD) and related non-AD tauopathies. Existing radiosyntheses of [18F]AV1451 require complex purifications to provide dose...

    Authors: Andrew V. Mossine, Allen F. Brooks, Bradford D. Henderson, Brian G. Hockley, Kirk A. Frey and Peter J. H. Scott
    Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:7
  15. Oncological pretargeting has been implemented and tested in several different ways in preclinical models and clinical trials over more than 30 years. Despite highly promising results, pretargeting has not achi...

    Authors: Clément Bailly, Caroline Bodet-Milin, Caroline Rousseau, Alain Faivre-Chauvet, Françoise Kraeber-Bodéré and Jacques Barbet
    Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:6
  16. Radiotheragnostics makes use of the same molecular targeting vectors, labeled either with a diagnostic or therapeutic radionuclide, ideally of the same chemical element. The matched pair of scandium radionucli...

    Authors: Katharina A. Domnanich, Cristina Müller, Martina Benešová, Rugard Dressler, Stephanie Haller, Ulli Köster, Bernard Ponsard, Roger Schibli, Andreas Türler and Nicholas P. van der Meulen
    Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:5
  17. The somatostatin receptor subtype 2 (sstr2) is expressed on a majority of luminal breast cancers, however SPECT and scintigraphy imaging with agonistic sstr2 probes has been sub-optimal. High affinity antagoni...

    Authors: Iulia Dude, Zhengxing Zhang, Julie Rousseau, Navjit Hundal-Jabal, Nadine Colpo, Helen Merkens, Kuo-Shyan Lin and François Bénard
    Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:4
  18. Radiolabeled phosphatidylserine (PS)-binding peptides represent an innovative strategy for molecular imaging of apoptosis and thrombus. The hexapeptide PGDLSR was described as a selective and high affinity lig...

    Authors: Rana Ben Azzouna, Alexandre Guez, Khadija Benali, Faisal Al-Shoukr, Walter Gonzalez, Philippe Karoyan, François Rouzet and Dominique Le Guludec
    Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:3
  19. The chemokine receptor 4 (CXCR4) is an important molecular target for both visualization and therapy of tumors. The aim of the present study was the synthesis and preclinical evaluation of a 64Cu-labeled, CXCR4-t...

    Authors: Andreas Poschenrieder, Margret Schottelius, Theresa Osl, Markus Schwaiger and Hans-Jürgen Wester
    Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:2
  20. αVβ3, αVβ5 and α5β1 integrins are known to be involved in carcinogenesis and are overexpressed in many types of tumours compared to healthy tissues; thereby they have been selected as promising therapeutic target...

    Authors: Didier J. Colin, James A. H. Inkster, Stéphane Germain and Yann Seimbille
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:16

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  21. Fast implementation of positron emission tomography (PET) into clinical and preclinical studies highly demands automated synthesis for the preparation of PET radiopharmaceuticals in a safe and reproducible man...

    Authors: Shihong Li, Alexander Schmitz, Hsiaoju Lee and Robert H. Mach
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:15

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  22. Bisphosphonates have a high adsorption on calcified tissues and are commonly used in the treatment of bone disorder diseases. Conjugates of bisphosphonates with macrocyclic chelators open new possibilities in ...

    Authors: M. Meckel, R. Bergmann, M. Miederer and F. Roesch
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:14

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  23. Positron Emission Tomography (PET), as a non-invasive translatable imaging technology, can be incorporated into various stages of the CNS drug discovery process to provide valuable information for key preclini...

    Authors: Lei Zhang and Anabella Villalobos
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:13

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  24. OP03 Selective extraction of medically-related radionuclides from proton-irradiated thorium targets

    Authors: V. Radchenko, J. W. Engle, C. Roy, J. Griswold, M. F. Nortier, E. R. Birnbaum, M. Brugh, S. Mirzadeh, K. D. John, M. E. Fassbender, Chuangyan Zhai, Gerben M. Franssen, Milos Petrik, Peter Laverman, Clemens Decristoforo, Ait-Mohand Samia…
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1(Suppl 1):10

    This article is part of a Supplement: Volume 1 Supplement 1

  25. Traditional nuclear medicine ligands were designed to target cellular receptors or transporters with a binding pocket and a defined structure–activity relationship. More recently, tracers have been developed t...

    Authors: Aleksandar Jovalekic, Norman Koglin, Andre Mueller and Andrew W. Stephens
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:11

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  26. 213Bismuth (213Bi, T1/2 = 45.6 min) is one of the most frequently used α-emitters in cancer research. High specific activity radioligands are required for peptide receptor radionuclide therap...

    Authors: Ho Sze Chan, Erik de Blois, Mark W. Konijnenberg, Alfred Morgenstern, Frank Bruchertseifer, Jeffrey P. Norenberg, Fred J. Verzijlbergen, Marion de Jong and Wouter A. P. Breeman
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:9

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  27. Recently, 44Sc (T1/2 = 3.97 h, Eβ+ av = 632 keV, I = 94.3 %) has emerged as an attractive radiometal candidate for PET imaging using DOTA-functionalized biomolecules. The aim of this study was...

    Authors: Katharina A. Domnanich, Cristina Müller, Renata Farkas, Raffaella M. Schmid, Bernard Ponsard, Roger Schibli, Andreas Türler and Nicholas P. van der Meulen
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:8

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  28. 6-[18F]Fluoro-L-3,4-dihydroxyphenylalanine (FDOPA) is a frequently used radiopharmaceutical for detecting neuroendocrine and brain tumors and for the differential diagnosis of Parkinson’s disease. To meet the dem...

    Authors: G. Luurtsema, H. H. Boersma, M. Schepers, A. M. T. de Vries, B. Maas, R. Zijlma, E. F. J. de Vries and P. H. Elsinga
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:7

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  29. Typically, metal-based radiopharmaceuticals are synthesized in aqueous solutions with no or low ethanol content. Labeling yields are defined by temperature, period of labeling, amount of precursor, pH etc. As ...

    Authors: Elisabeth Eppard, Marylaine Pèrez-Malo and Frank Rösch
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:6

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  30. 149Tb represents a powerful alternative to currently used α-emitters: the relatively short half-life (T1/2 = 4.1 h), low α-energy (3.97 MeV, Iα = 16.7 %), absence of α-emitting daughters and stab...

    Authors: Cristina Müller, Christiaan Vermeulen, Ulli Köster, Karl Johnston, Andreas Türler, Roger Schibli and Nicholas P. van der Meulen
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:5

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  31. The widespread acceptance and application of 68Ga-PET depends on our ability to develop radiopharmaceuticals that can be prepared in a convenient and suitable manner. A kit-type labelling protocol provides such c...

    Authors: Johanna Seemann, Bradley Waldron, David Parker and Frank Roesch
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:4

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  32. Phosphodiesterase 10A (PDE10A) is an important regulator of nigrostriatal dopamine (DA) neurotransmission. However, little is known on the effect of alterations in DA neurotransmission on PDE10A availability. ...

    Authors: Maarten Ooms, Sofie Celen, Ronald De Hoogt, Ilse Lenaerts, Johnny Liebregts, Greet Vanhoof, Xavier Langlois, Andrey Postnov, Michel Koole, Alfons Verbruggen, Koen Van Laere and Guy Bormans
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:3

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  33. This is a position paper of the Radiopharmacy Committee of the EANM (European Association of Nuclear Medicine) addressing toxicology studies for application of new diagnostic and therapeutic radiopharmaceutica...

    Authors: J. Koziorowski, M. Behe, C. Decristoforo, J. Ballinger, P. Elsinga, V. Ferrari, P. Kolenc Peitl, S. Todde and T. L. Mindt
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:1

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

EJNMMI Reports - Kindly explore our collections here

Topical Collections about latest and interesting topics in EJNMMI Radiopharmacy and Chemistry are available at: https://link.springer.com/journal/41824/collections

EANM'24 - Future Congress!

EANM'24 banner horizontal

Future Congress

37th Annual Congress of the European Association of Nuclear Medicine

October 19 – 23, 2024
Hamburg, Germany


CCH – Congress Center Hamburg
Congressplatz 1
20355 Hamburg, Germany
URL: https://www.cch.de/en/

EJNMMI Journal Family and EANM Springer Award

New Content Item

EJNMMI is part of the EJNMMI Journal Family. Highlights of our featured content and the latest developments from the EJNMMI group of journals can be found on the EJNMMI Journal Family webpage. There details about the annual EANM Springer Award are available as well.


Do you want to publish your paper open access?

Details of the OpenChoice option in EJNMMI are available in the submission guidelines.

If your institution has a Read and Publish (Springer Compact) agreement, you may publish your article open access at no cost to you. In addition, you can enjoy full access to all Springer subscription journal content.

Please check the agreement details by participating country here.